Want to see IN:ASTRAZEN full AI Analyst Report?
ASTRAZEN Stock Chart & Stats
₹8431.70
₹585.60(8.51%)
At close: 4:00 PM EST
₹8431.70
₹585.60(8.51%)
Day’s Range― - ―
52-Week Range₹5,889.10 - ₹9,850.00
Previous CloseN/A
Volume65.42K
Average Volume (3M)555.00
Market Cap
₹150.76B
Enterprise Value₹190.61B
Total Cash (Recent Filing)₹4.48B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)88.6
Beta0.76
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.6%
Share Statistics
EPS (TTM)67.85
Shares Outstanding25,000,000
10 Day Avg. Volume555
30 Day Avg. Volume555
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)22.24
Price to Sales (P/S)8.53
P/FCF Ratio6.05K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong FY2026 revenue growth indicates continued demand for the company’s branded prescription portfolio in India. Sustained top-line expansion can support broader commercial reach, reinforce relationships with healthcare providers and channels, and provide a foundation for future earnings growth.
Low Financial LeverageThe company remains conservatively financed despite debt increasing during FY2026. Low debt relative to equity supports solvency, limits interest burden, and preserves financial flexibility to sustain operations or invest in its branded specialty-medicine platform through changing conditions.
Diversified Specialty PortfolioCoverage across multiple specialty therapeutic areas reduces reliance on a single disease category or product group. This breadth can support more resilient prescription demand, diversify commercial opportunities, and strengthen the company’s position with healthcare providers and institutional channels.
Bears Say
Cash Flow CollapseThe sharp deterioration in operating and free cash flow weakens the quality of recent earnings and reduces internally generated funding. Poorer cash conversion can constrain reinvestment, dividends, or other capital allocation and signals greater exposure to cash-use volatility.
Margin CompressionThe substantial decline in gross and operating margins shows that revenue growth is not translating into comparable profitability. If the weaker product mix or cost pressure persists, it could reduce earnings resilience and limit the operating leverage expected from continued sales expansion.
Declining EPSNegative EPS growth indicates that per-share earnings are weakening even as the company reports revenue expansion. This divergence highlights pressure on profitability or earnings conversion and could make sustained shareholder returns more dependent on restoring operating performance.
AstraZeneca Pharma India Limited News
ASTRAZEN FAQ
What was AstraZeneca Pharma India Limited’s price range in the past 12 months?
AstraZeneca Pharma India Limited lowest stock price was ₹5889.10 and its highest was ₹9850.00 in the past 12 months.
What is AstraZeneca Pharma India Limited’s market cap?
AstraZeneca Pharma India Limited’s market cap is ₹150.76B.
When is AstraZeneca Pharma India Limited’s upcoming earnings report date?
AstraZeneca Pharma India Limited’s upcoming earnings report date is Nov 14, 2026 which is in 39 days.
How were AstraZeneca Pharma India Limited’s earnings last quarter?
AstraZeneca Pharma India Limited released its earnings results on Aug 10, 2026. The company reported ₹15.172 earnings per share for the quarter.
Is AstraZeneca Pharma India Limited overvalued?
According to Wall Street analysts AstraZeneca Pharma India Limited’s price is currently Overvalued.
Does AstraZeneca Pharma India Limited pay dividends?
AstraZeneca Pharma India Limited pays a Annually dividend of ₹36 which represents an annual dividend yield of 0.6%. See more information on AstraZeneca Pharma India Limited dividends here
What is AstraZeneca Pharma India Limited’s EPS estimate?
AstraZeneca Pharma India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AstraZeneca Pharma India Limited have?
AstraZeneca Pharma India Limited has 25,000,000 shares outstanding.
What happened to AstraZeneca Pharma India Limited’s price movement after its last earnings report?
AstraZeneca Pharma India Limited reported an EPS of ₹15.172 in its last earnings report. Following the earnings report the stock price went down -1.354%.
Which hedge fund is a major shareholder of AstraZeneca Pharma India Limited?
Currently, no hedge funds are holding shares in IN:ASTRAZEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The company offers an extensive range of medications, including treatments for cardiovascular conditions and diabetes, marketed under brands such as Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN. Its respiratory portfolio features products like Symbicort and FASENRA, while its oncology division provides various cancer therapies, including LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex. Furthermore, the firm extends its product line to encompass therapeutic solutions for renal, metabolic, and immunological disorders. Beyond its pharmaceutical offerings, AstraZeneca Pharma India Limited also provides clinical trial services. Established in 1979, the company is based in Bengaluru, India, and functions as a subsidiary of AstraZeneca Pharmaceuticals AB.
Technical Analysis
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―